All In Biotech

Free tool

FAERS Monitor: Bonjesta

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 209661 or its brand name (Bonjesta, Doxylamine Succinate, Pyridoxine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

153

Serious

71

46% of reports

Hospitalization

36

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • maternal exposure during pregnancy25
  • nausea17
  • drug ineffective16
  • exposure during pregnancy16
  • off label use13
  • abortion spontaneous12
  • product use in unapproved indication10
  • serotonin syndrome10
  • somnolence10
  • vomiting10
  • drug ineffective for unapproved indication9
  • foetal exposure during pregnancy8
  • anxiety6
  • fatigue6
  • vision blurred6

Reports by year received

View as table
YearReports
201822
201928
202012
202116
202221
202316
202415
202513
202610

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,006 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
serotonin syndromeSignal1071.639.3628
abortion spontaneousSignal1241.223.9432
maternal exposure during pregnancySignal2538.626.9881
exposure during pregnancySignal1635.422.3502
drug ineffective for unapproved indicationSignal922.512.0165
foetal exposure during pregnancySignal813.56.981
somnolenceSignal106.83.745
vision blurredSignal66.02.720
product use in unapproved indicationSignal105.53.033
nauseaSignal173.01.921
vomitingSignal102.91.611
anxietySignal62.91.36
off label useSignal132.01.26
drug ineffective161.71.04
fatigue61.10.50

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.